Bioactive nanotherapeutic trends to combat triple negative breast cancer

Abstract

The management of aggressive breast cancer, particularly, triple negative breast cancer (TNBC) remains a formidable challenge, despite treatment advancement. Although newer therapies such as atezolizumab, olaparib, and sacituzumab can tackle the breast cancer prognosis and/or progression, but achieved limited survival benefit(s). The current research efforts are aimed to develop and implement strategies for improved bioavailability, targetability, reduce systemic toxicity, and enhance therapeutic outcome of FDA-approved treatment regimen. This review presents various nanoparticle technology mediated delivery of chemotherapeutic agent(s) for breast cancer treatment. This article also documents novel strategies to employ cellular and cell membrane cloaked (biomimetic) nanoparticles for effective clinical translation. These technologies offer a safe and active targeting nanomedicine for effective management of breast cancer, especially TNBC.

Investigating the Impact of Optimized Trans-Cinnamic Acid-Loaded PLGA Nanoparticles on Epithelial to Mesenchymal Transition in Breast Cancer

“… 1 It is classified into hormone receptor-positive, human epidermal growth factor receptor-2 (HER2) overexpressing and triple-negative breast cancer, 2 the latter being clinically characterized by the negative expression of progesterone receptor (PR), estrogen receptor (ER), and HER2. 3 Triple-negative breast cancer is considered the most aggressive and heterogeneous subtype of breast cancer stemming from its ability to grow rapidly and metastasize to the viscera, particularly the lungs and the brain. Therefore, its aggressive nature, metastatic potential, and lack of receptor/target expression presents conventional chemotherapy as the pillar for treating triple-negative breast cancer.…”

“…Therefore, its aggressive nature, metastatic potential, and lack of receptor/target expression presents conventional chemotherapy as the pillar for treating triple-negative breast cancer. 3 Chemotherapy, however, is toxic to non-cancerous cells and frequently leads to rapid development of acquired resistance in tumor cells, owing to the upregulation of multidrug resistance (MDR) transporters. 4 In addition, chemotherapy has a fast clearance, low therapeutic efficacy, uncontrolled drug release behavior, and lack of selectivity.…”

DataSheet2.CDX

“…Breast cancer is still the most common cancer among women (Chowdhury et al, 2021;Loibl et al, 2021). The incidence rate accounts for about 30%, and the mortality rate is as high as 15% (Loibl et al, 2021).…”

“…The incidence rate accounts for about 30%, and the mortality rate is as high as 15% (Loibl et al, 2021). Triple-negative breast cancer (TNBC) is one of the subgroups of breast cancer which has an incidence of 15-20% and many characteristics such as invasive, resistant, and rapid growth rate (Chen et al, 2021;Chowdhury et al, 2021). Due to its aggressive behavior, metastasis usually occurs in the liver, lungs, and brain (Chen et al, 2021;Chowdhury et al, 2021).…”

“…Triple-negative breast cancer (TNBC) is one of the subgroups of breast cancer which has an incidence of 15-20% and many characteristics such as invasive, resistant, and rapid growth rate (Chen et al, 2021;Chowdhury et al, 2021). Due to its aggressive behavior, metastasis usually occurs in the liver, lungs, and brain (Chen et al, 2021;Chowdhury et al, 2021). Discovering some potential molecules which could inhibit cell migration of TNBC may provide some enlightenment for its treatment.…”